Key clinical point: The MET inhibitor tepotinib produced responses in about half of advanced non–small cell lung cancer patients with confirmed MET exon 14–skipping mutations.

Major finding: The response rate was 46.5% according to independent reviewers and 55.6% according to investigators. There were no complete responses according to reviewers and two complete responses per investigators.

Study details: A phase 2 study of 152 patients, 99 of whom had at least 9 months of follow-up.

Disclosures: The study was funded by Merck. The investigators disclosed relationships, including employment, with the company.